PHA/RMA News
DexCom (DXCM) Releases Q2 2026 Earnings Presentation as CGM Leader Navigates Competitive Landscape
DexCom Q2 2026 earnings presentation released as CGM leader navigates GLP-1 headwinds and competitive pressure
Aug 1, 2026
๐บ๐ธ United StatesMadrigal and Phathom Both Beat Q2 Revenue Estimates as Specialty Pharma Launches Hold Firm
Madrigal Pharmaceuticals (MDGL) and Phathom Pharmaceuticals (PHAT) both posted Q2 2026 revenue beats, validating commercial execution for Rezdiffra MASH launch and Phathom's acid-suppression pipeline.
Jul 31, 2026
๐จ๐ฆ CanadaAbbVie Q2 Beats on Immunology Strength as Botox Shows Revival Signs
AbbVie Q2 profit and sales beat Wall Street estimates driven by immunology and neuroscience franchise strength, with early signs of Botox recovery easing concerns about its aesthetics division plateau.
Jul 31, 2026
๐ฉ๐ช GermanyEuroapiS Shares Crash 23% to Record Low โฌ0.93 as H1 2026 Loss Deepens, YTD Decline Hits 57%
EuroapiS fell 23% to a record low of โฌ0.93 after reporting deeply negative H1 2026 results, with year-to-date losses hitting 57% as the pharmaceutical ingredient manufacturer faces structural margin pressure from Chinese API competition.
Jul 31, 2026
๐ฉ๐ช GermanySanofi and CRH Shares Plunge Despite Record Results as Markets Demand More
Sanofi shares fell 9.33% despite raising full-year 2026 guidance following a strong second quarter driven by Dupixent record sales
Jul 30, 2026
๐ฉ๐ช GermanyPharming Group Crashes 20.65% as Q2 Revenue Falls Short of Targets
Pharming Group shares plunged over 20% Thursday after preliminary Q2 results showed significant revenue shortfall
Jul 30, 2026
๐ฉ๐ช GermanyUCB Shares Crash 13.9% as Market Punishes Belgian Biopharma Despite H1 Revenue Up 22%
UCB shares fell 13.88% despite H1 revenue rising 22% to โฌ4.27 billion and management raising guidance
Jul 30, 2026
๐ฉ๐ช GermanyMarinomed Biotech Shares Crash 10.71% After Austrian Biotech Files for Court Insolvency
Marinomed Biotech shares fell 10.71% to โฌ5 after the Austrian biopharma filed for court-supervised insolvency proceedings following financing collapse
Jul 30, 2026
๐ฎ๐ณ IndiaRPGLS Eyes โน700-1,000 Crore Plant Acquisition to Launch Semaglutide in India
RPGLS plans semaglutide launch in India, investing โน700-1,000 crore for manufacturing facility acquisition
Jul 30, 2026
๐บ๐ธ United StatesSynlogic Merger With Caldera Therapeutics Meets Market Skepticism Amid High Valuation
Synlogic (SYBX) is merging with Caldera Therapeutics in a deal that faces investor skepticism
Jul 30, 2026
๐บ๐ธ United StatesAnika Therapeutics Q2 Earnings Beat Amid Recovery, GF Score 64 Flags Execution Risk
Anika Therapeutics (ANIK) reported a Q2 2026 earnings beat, signalling potential recovery momentum
Jul 30, 2026
๐ง๐ท BrazilChrysCapital Acquires 70.68% Controlling Stake in Novartis India in Landmark Pharma Deal
Private equity firm ChrysCapital has acquired a 70.68% controlling stake in Novartis India Limited
Jul 30, 2026
๐ฉ๐ช GermanyGerresheimer Divests Centor and Primary Packaging Plastics to Apax Partners in Strategic Refocus
Gerresheimer AG is divesting its Centor unit and global Primary Packaging Plastics business to Apax Partners funds in a strategic portfolio reshaping toward glass and medical devices
Jul 29, 2026
๐บ๐ธ United StatesIQVIA Holdings Raises FY26 Guidance After Q2 Beat; Shares Surge 10.6%
IQVIA Holdings raised its adjusted earnings and revenue guidance for full-year 2026 after Q2 results showed stronger-than-expected organic revenue growth
Jul 29, 2026
๐ฎ๐ณ IndiaIndia Pharma Mid-Cap Hits Record High After Q1 Beat; 10% Gain in Five Days
An India mid-cap pharma stock delivered 10% returns over five days and hit a record high after reporting strong Q1 FY27 results that exceeded analyst expectations on both revenue and profitability metrics.
Jul 29, 2026
๐ฎ๐ณ IndiaAstraZeneca EPS Surges 21% to $2.63 as Oncology Portfolio Beats Estimates
AstraZeneca adjusted EPS climbed 21% to $2.63, comfortably surpassing analyst expectations in the latest quarter
Jul 28, 2026
๐บ๐ธ United StatesGossamer Bio (GOSS) Opens Discussions to Reacquire Rights to Seralutin, Signaling Renewed Pipeline Confidence
Gossamer Bio (NASDAQ: GOSS) disclosed it is in discussions to reacquire rights to seralutin (GB004), a gut-selective S1P1 receptor modulator previously out-licensed
Jul 28, 2026
๐บ๐ธ United Statesargenx Acquires Forte Biosciences for $2.2 Billion to Expand Immunology Portfolio Beyond Vyvgart Into Inflammatory Dermatology
argenx SE (ARGX) agreed to acquire Forte Biosciences (FBRX) for approximately $2.2 billion, expanding its immunology pipeline into inflammatory skin disease treatments
Jul 28, 2026
๐บ๐ธ United StatesEntera Bio Raises $275 Million in Private Placement to Advance Oral PTH Therapy EB613 Toward NDA Filing
Entera Bio raised $275 million in a private placement to fund advancement of EB613, its oral parathyroid hormone therapy for osteoporosis
Jul 28, 2026
๐ GlobalCurium Said to Near $7 Billion Acquisition of Lantheus Holdings in Radiopharma Consolidation Play
Curium is in advanced talks to acquire Lantheus Holdings (LNTH) for approximately $7 billion, per Bloomberg sources
Jul 28, 2026
๐ง๐ท BrazilACA Coverage Debate Creates $50 Billion Valuation Risk for Intuitive Surgical's Robotic Surgery Market
The US ACA coverage debate has put approximately $50 billion in valuation risk on the table for Intuitive Surgical, the robotic surgery market leader
Jul 28, 2026
๐ฎ๐ณ IndiaLaurus Labs Reaches Record High on Multiple Upgrades as Kotak Holds 33% Downside Call
Laurus Labs shares hit an all-time record high following multiple analyst upgrades post-Q1 results
Jul 28, 2026
๐บ๐ธ United StatesForte Biosciences Soars 39% After Argenx Announces Acquisition of Atopic Dermatitis Biotech
Forte Biosciences (FBRX) shares surged 39% after Belgian immunology company argenx announced a deal to acquire the atopic dermatitis-focused biotech
Jul 28, 2026
๐บ๐ธ United StatesUnicycive Therapeutics: Two FDA CRLs, One Fixable Problem โ Tight Cash Runway Amplifies Binary Risk
Unicycive Therapeutics (UNCY) has received two FDA CRLs, with at least one characterized as a fixable regulatory deficiency rather than clinical failure
Jul 26, 2026
๐บ๐ธ United StatesInhibrx Biosciences: INBRX-106 Carries All the Value as FDA CRL Setbacks Meet Tight Cash Runway
Inhibrx Biosciences' entire investment thesis hinges on INBRX-106 clinical success, with tight cash runway amplifying the binary risk profile
Jul 26, 2026
๐บ๐ธ United StatesPfizer's 6.8% Dividend Yield Looks Almost Too Good โ Here's Why Management Says It's Sustainable
Pfizer's dividend yield has reached 6.8%, far above the market average of roughly 1%, raising questions about sustainability
Jul 26, 2026
๐ฉ๐ช GermanyEli Lilly Mounjaro Projected to Hit $20 Billion in Annual Sales by 2027 as GLP-1 Market Explodes
Analysts project Eli Lilly's Mounjaro (tirzepatide) will generate $20 billion or more in annual revenue by 2027, making it the fastest drug to blockbuster status in history; Mounjaro's dual GIP and GLP-1 receptor agonist mechanism delivers superior weight loss versus Novo Nordis
Jul 26, 2026
๐ฌ๐ง United KingdomAstraZeneca Q2 2026 Earnings Due July 27 With Consensus EPS Estimate at $1.27
AstraZeneca (AZN) is scheduled to report Q2 2026 earnings on Monday, July 27, before market open
Jul 25, 2026
๐บ๐ธ United StatesMannKind Shares Surge After FDA Drug Approval; Company Raises 0M in Equity Placement
MannKind shares surged after FDA approved its drug product, resolving binary regulatory risk; 0M equity placement secures runway.
Jul 25, 2026
IndiaSun Pharma's $11.75 Billion Organon Acquisition Clears Shareholder Vote
Organon shareholders approved Sun Pharma's $11.75 billion acquisition proposal, clearing a key deal milestone as Organon moves toward becoming a wholly owned Sun Pharma subsidiary.
Jul 25, 2026